- Home
- VRCA vs ALGS Comparison
VRCA vs ALGS Comparison
Compare VRCA & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | ALGS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 57.2M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VRCA | ALGS |
|---|---|---|
| Price | $8.42 | $10.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 359.1K | 82.8K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,829,000.00 | $2,646,000.00 |
| Revenue This Year | $332.45 | N/A |
| Revenue Next Year | $12.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $3.76 |
| 52 Week High | $12.50 | $46.80 |
Technical Indicators
Market Signals| Indicator | VRCA | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 70.38 | 64.23 |
| Support Level | $6.26 | $9.10 |
| Resistance Level | $9.82 | $7.00 |
| Average True Range (ATR) | 0.90 | 0.73 |
| MACD | 0.42 | 0.27 |
| Stochastic Oscillator | 77.65 | 92.24 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.